HT-4253

DRUG2 trials

Sponsors

Halia Therapeutics, Inc.

Conditions

Alzheimers DiseaseNormal Healthy Subjects

Phase 1

Study to Evaluate HT-4253 in Healthy Subjects

CompletedNCT06537817

Halia Therapeutics, Inc.Normal Healthy Subjects

Start: 2024-09-17End: 2025-05-12Updated: 2025-06-11

Phase 2

Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers

RecruitingNCT07399171

Halia Therapeutics, Inc.Alzheimers Disease

Start: 2026-05-12End: 2028-07-01Target: 112Updated: 2026-08-05